Catalyst briefs
What to know before each readout
One page per upcoming Phase 3 readout at a listed company. Facts first, each with its source. Rebuilt every night.
| Days | Ticker | Trial | Registry date | Facts | Analyst desk |
|---|---|---|---|---|---|
| 12 | VNDA | Tradipitant | 1 Dec 2026 | 17 | yes |
| 26 | AXSM | ENGAGE | Dec 2026 | 19 | yes |
| 26 | MDWD | VALUE | Dec 2026 | 13 | yes |
| 26 | KRYS | IOLITE | Dec 2026 | 16 | yes |
| 26 | PRAX | EMERALD | Dec 2026 | 20 | yes |
| 26 | UTHR | Ralinepag | Dec 2026 | 15 | yes |
| 26 | MANE | VDPHL01 | Dec 2026 | 15 | yes |
| 26 | VIR | Tobevibart | Dec 2026 | 16 | yes |
| 26 | EXEL | STELLAR-304 | 15 Dec 2026 | 18 | yes |
| 26 | IONS | Donidalorsen | Dec 2026 | 19 | yes |
| 26 | DMAC | ReMEDy2 | Dec 2026 | 16 | yes |
| 26 | KPTIQ | Selinexor (combination therapy) | Dec 2026 | 18 | yes |
How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.